GO
Loading...

Pharmaceuticals

More

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • Former Va. governor's corruption case goes to jury Tuesday, 2 Sep 2014 | 3:03 AM ET

    RICHMOND, Va.— The corruption case that could send former Virginia Gov. Bob and Maureen McDonnell are charged in a 14- count federal indictment with accepting more than $165,000 in gifts, trips and loan from Jonnie Williams, former CEO of dietary supplements maker Star Scientific Inc., in exchange for special favors.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to close near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • European shares tick higher, drugmakers advance Monday, 1 Sep 2014 | 11:17 AM ET

    *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares traded near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers. Novartis, up 4.7 percent, was the top gainer on the FTSEurofirst 300 index.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to trade near a recent one-month peak on Monday, with mergers and acquisitions speculation surrounding British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • Senate hopeful defends role in Irish firm's merger Friday, 29 Aug 2014 | 4:12 PM ET

    ST. PAUL, Minn.— Years before Burger King sized up a Canadian headquarters in a hunt for lower taxes, Republican U.S. Senate candidate Mike McFadden's investment firm was involved in a merger that moved an American pharmaceutical company to Ireland and significantly dropped its tax rate.

  • United Therapeutics rises on drug-patent ruling Friday, 29 Aug 2014 | 2:01 PM ET

    NEW YORK— Shares of United Therapeutics jumped Friday after the company said a court ruled in its favor in a patent dispute over its blood pressure drug Remodulin. United Therapeutics said a judge for the U.S. District Court for the District of New Jersey ruled that drugmaker Sandoz can't market a generic version of Remodulin until October 2017.

  • MUMBAI, Aug 29- Indian drugmakers are fleeing a regulatory morass at home and moving some research and development to Europe and the United States as try to boost margins by producing high-value drugs.

  • Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

  • Kite Pharma's positive cancer drug study results     Wednesday, 27 Aug 2014 | 2:25 PM ET

    Kite Pharma is working on a treatment which involves taking a cancer patient's own t-cells out of their body, genetically modifying them to better target cancer, and then re-administering them. Its CEO Arie Belldegrun, provides insight to the positive study with the therapy.

  • 3 ways insurers can discourage sick from enrolling Wednesday, 27 Aug 2014 | 10:35 AM ET

    Insurers can no longer reject customers with expensive medical conditions thanks to the health care overhaul, but there's still wiggle room for them to discourage the sickest and costliest patients from enrolling.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Ebola is 'contained' in Nigeria: Health minister Tuesday, 26 Aug 2014 | 12:05 PM ET
    A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July 26, 2014.

    Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Roche's blockbuster pharma deal     Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • Roche CEO: InterMune perfect strategic fit     Monday, 25 Aug 2014 | 11:18 AM ET

    CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.

  • Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to buy US biotech firm InterMune for $8.3B Sunday, 24 Aug 2014 | 12:49 PM ET

    BERLIN— Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California- based developer of treatments for lung diseases. The companies have reached an agreement under which Roche will acquire InterMune in an all-cash transaction, paying $74.00 per InterMune share, Roche said.